GlobeNewswire Inc.··Priovant Therapeutics / Roivant SciencesPriovant's Brepocitinib Clears Phase 3 Trial for Rare Muscle Disease, Eyes 2026 FDA Approval
Priovant's brepocitinib met Phase 3 endpoints for dermatomyositis treatment, earning FDA Priority Review with Q3 2026 decision expected.
ROIVclinical trial resultsautoimmune disease